- LIST OF FIGURES
- SUMMARY
- 1. INTRODUCTION
- 2. PROBLEMS INVOLVED IN DEVELOPING DRUGS
- 2.1 DRUG INNOVATION AS AN INVESTMENT UNDER UNCERTAINTY
- 2.2 THE ROLE OF PATENTS
- 3. ON THE OPTIMAL DRUG PRICING
- 3.1 MONOPOLY DRUG PRICING DURING PATENT PROTECTION
- 3.2 DRUG PRICING UNDER COMPETITION (WITHOUT PATENT)
- 4. EXPERIENCES OF REFERENCE PRICES IN THE GERMAN DRUG MARKET
- 4.1 INTRODUCING REFERENCE PRICE SYSTEM IN 1989
- 5.2 THE EFFECTS OF REFERENCE PRICES FOR THE GERMAN DRUG MARKET
- 5. CONCLUDING REMARKS
- 5.1 MAIN FINDINGS
- 5.2 ON THE PRICING METHOD SUGGESTED BY CIPE
- REFERENCES
Persistent link: https://www.econbiz.de/10005855822